Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) a Buy, Sell, or Hold?
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$9.03 USD
-$0.01 (-0.11%)
- Volume
- 326.57K
- Average Volume
- 504.28K
- Market Capitalization
- $113.2M
- P/E Ratio
- -1.37
- Dividend Yield
- 0.00%
- Price Target
- $38.50
- Year High
- $20.56
- Year Low
- $7.12
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.92
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Yuval Cohen |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRBP |
| CUSIP | 21833P301 |
| CIK | 0001595097 |
| Web | https://www.corbuspharma.com |
| Phone | 617 963 0100 |
| Currency | USD |
| Employees | 36 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.92 |
| Quick Ratio | 7.92 |
| Cash Ratio | 1.44 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -5.53 |
| Price / Cash Flow | -1.54 |
| Price / Book | 0.95 |
Price Target and Rating
| Average Stock Price Forecast | $38.50 |
| High Stock Price Forecast | $44.00 |
| Low Stock Price Forecast | $33.00 |
| Forecast Upside/Downside | -76.55% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.9 |
| Trailing P/E Ratio | -1.37 |
| PEG Ratio | 0.14 |
| P/E Growth | 0.14 |
| Net Income | $-78.54M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -70.89% |
| Return on Assets | -58.50% |
Financials Score
| AltmanZ Score | -2.74 |
| Piotroski Score | 1.00 |
| Working Capital | 125.43M |
| Total Assets | 144.48M |
| Ebit | -84.53M |
| Market Cap | 113.32M |
| Total Liabilities | 18.14M |
Poll Results
About Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Stock
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA. ...
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
2026-07-06 08:00:00
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Leonardo Viana Nicacio, M.D.
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near
2026-06-09 05:02:22
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Yuval Cohen outlined the company's near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
2026-06-01 13:34:04
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
2026-06-01 10:05:21
Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company's CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human papillomavirus, or HPV.
2026-05-26 13:37:06
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
2026-05-26 07:00:00
NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study (NCT06265727) of CRB-701 (SYS6002), a next-generation Nectin-4 targeted antibody drug conjugate (ADC). The new data demonstrate robust activity in the second line (2L) setting of two solid tumor types that express high levels of Nectin-4 and are primarily driven by human papilloma virus (HPV): oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer. These findings will be presented at the upcoming 2026 American Society for Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago.
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
2026-05-22 03:05:33
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company's highlighted cervical and head and neck cancer cohorts.
2026-05-21 08:00:00
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m.
Frequently Asked Questions
-
What is the current Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock price?
-
Corbus Pharmaceuticals Holdings, Inc.(NASDAQ:CRBP) stock price is $9.03 in the last trading session. During the trading session, CRBP stock reached the peak price of $20.56 while $7.12 was the lowest point it dropped to. The percentage change in CRBP stock occurred in the recent session was --0.11% while the dollar amount for the price change in CRBP stock was -$-0.01.
-
CRBP's industry and sector of operation?
-
The NASDAQ listed CRBP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRBP?
-
Leonardo Viana Nicacio | Chief Medical Officer
Dominic Smethurst | Chief Medical Officer
Ian Hodgson | Chief Operating Officer
Yuval Cohen | Chief Executive Officer & Director
G. Scott Goeken | General Counsel & Corporate Secretary -
How many employees does CRBP have?
-
Number of CRBP employees currently stands at 36. CRBP operates from 500 River Ridge Drive, Norwood, MA 02062, US.
-
Link for CRBP official website?
-
Official Website of CRBP is: https://www.corbuspharma.com
-
How do I contact CRBP?
-
CRBP could be contacted at phone #617 963 0100 and can also be accessed through its website. CRBP operates from 500 River Ridge Drive, Norwood, MA 02062, US.
-
How many shares of CRBP are traded daily?
-
The average number of CRBP shares traded daily for last 3 months was 504.28K.
-
What is the market cap of CRBP currently?
-
The market value of CRBP currently stands at $113.2M with its latest stock price at $9.03